$PRPH
ProPhase Labs, Inc.

2013 Q2 Form 10-Q Financial Statement

#000114420413045279 Filed on August 13, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2012 Q2
Revenue $1.939M $1.894M
YoY Change 2.38% 8.85%
Cost Of Revenue $1.011M $1.069M
YoY Change -5.43% 25.76%
Gross Profit $928.0K $825.0K
YoY Change 12.48% -8.33%
Gross Profit Margin 47.86% 43.56%
Selling, General & Admin $2.430M $2.228M
YoY Change 9.07% 31.06%
% of Gross Profit 261.85% 270.06%
Research & Development $216.0K $529.0K
YoY Change -59.17% 193.89%
% of Gross Profit 23.28% 64.12%
Depreciation & Amortization $60.00K $60.00K
YoY Change 0.0% -33.33%
% of Gross Profit 6.47% 7.27%
Operating Expenses $2.646M $2.757M
YoY Change -4.03% 46.65%
Operating Profit -$1.718M -$1.932M
YoY Change -11.08% 97.14%
Interest Expense $2.000K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.719M -$1.930M
YoY Change -10.93% 98.97%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.719M -$1.930M
YoY Change -10.93% 98.97%
Net Earnings / Revenue -88.65% -101.9%
Basic Earnings Per Share -$0.11 $0.13
Diluted Earnings Per Share -$0.11 $0.13
COMMON SHARES
Basic Shares Outstanding 15.85M shares 14.83M shares
Diluted Shares Outstanding 15.85K shares 14.83M shares

Balance Sheet

Concept 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.060M $4.610M
YoY Change -11.93% -47.25%
Cash & Equivalents $4.058M $4.610M
Short-Term Investments
Other Short-Term Assets $520.0K $490.0K
YoY Change 6.12% 63.33%
Inventory $3.289M $3.140M
Prepaid Expenses
Receivables $1.128M $940.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $8.995M $9.180M
YoY Change -2.02% -22.2%
LONG-TERM ASSETS
Property, Plant & Equipment $2.495M $2.420M
YoY Change 3.1% 2.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.072M $6.000M
YoY Change 1.2% 0.84%
TOTAL ASSETS
Total Short-Term Assets $8.995M $9.180M
Total Long-Term Assets $6.072M $6.000M
Total Assets $15.07M $15.18M
YoY Change -0.74% -14.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.027M $530.0K
YoY Change 93.77% 307.69%
Accrued Expenses $2.180M $5.410M
YoY Change -59.7% 1.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.471M $6.400M
YoY Change -30.14% 10.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K
YoY Change
Total Long-Term Liabilities $300.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.471M $6.400M
Total Long-Term Liabilities $300.0K $0.00
Total Liabilities $4.771M $6.400M
YoY Change -25.45% 10.54%
SHAREHOLDERS EQUITY
Retained Earnings -$7.219M
YoY Change
Common Stock $43.15M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $25.64M
YoY Change
Treasury Stock Shares 5.336M shares
Shareholders Equity $10.30M $8.770M
YoY Change
Total Liabilities & Shareholders Equity $15.07M $15.18M
YoY Change -0.74% -14.48%

Cashflow Statement

Concept 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$1.719M -$1.930M
YoY Change -10.93% 98.97%
Depreciation, Depletion And Amortization $60.00K $60.00K
YoY Change 0.0% -33.33%
Cash From Operating Activities -$240.0K -$1.480M
YoY Change -83.78% 127.69%
INVESTING ACTIVITIES
Capital Expenditures -$240.0K -$180.0K
YoY Change 33.33% -5.26%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$240.0K -$180.0K
YoY Change 33.33% -10.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -240.0K -1.480M
Cash From Investing Activities -240.0K -180.0K
Cash From Financing Activities 0.000
Net Change In Cash -480.0K -1.660M
YoY Change -71.08% 95.29%
FREE CASH FLOW
Cash From Operating Activities -$240.0K -$1.480M
Capital Expenditures -$240.0K -$180.0K
Free Cash Flow $0.00 -$1.300M
YoY Change -100.0% 182.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3980000 USD
dei Document Type
DocumentType
10-Q
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15799000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14811000 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
79000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
195000 USD
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Trading Symbol
TradingSymbol
PRPH
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15858787 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
572000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5409000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
2051000 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2687000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
10719000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2365000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3577000 USD
CY2012Q4 us-gaap Assets
Assets
16661000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1296000 USD
dei Entity Registrant Name
EntityRegistrantName
ProPhase Labs, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000868278
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4471000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3860000 USD
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0005
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0005
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21181115 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21056115 shares
CY2013Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
5336053 shares
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5336053 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4058000 USD
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1128000 USD
CY2013Q2 us-gaap Inventory Net
InventoryNet
3289000 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
520000 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
8995000 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2495000 USD
CY2013Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3577000 USD
CY2013Q2 us-gaap Assets
Assets
15067000 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1027000 USD
CY2013Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2184000 USD
CY2012Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2760000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4910000 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
11000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
11000 USD
CY2013Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43141000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42867000 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7219000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5790000 USD
CY2013Q2 us-gaap Treasury Stock Value
TreasuryStockValue
25637000 USD
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
25637000 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
10296000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
11451000 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15067000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16661000 USD
CY2013Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
300000 USD
CY2012Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
300000 USD
CY2013Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1260000 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
854000 USD
CY2013Q2 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
300000 USD
CY2012Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
300000 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Sales Revenue Net
SalesRevenueNet
9481000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
7912000 USD
CY2013Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1011000 USD
CY2012Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1069000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3214000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2747000 USD
CY2013Q2 us-gaap Gross Profit
GrossProfit
928000 USD
CY2012Q2 us-gaap Gross Profit
GrossProfit
825000 USD
us-gaap Gross Profit
GrossProfit
6267000 USD
us-gaap Gross Profit
GrossProfit
5165000 USD
CY2013Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
709000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.11
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3997000 USD
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1939000 USD
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1894000 USD
CY2012Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
820000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4072000 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1723000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1408000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3221000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2900000 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
216000 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
529000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
404000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
890000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
2648000 USD
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
2757000 USD
us-gaap Operating Expenses
OperatingExpenses
7697000 USD
us-gaap Operating Expenses
OperatingExpenses
7787000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1720000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1932000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1430000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2622000 USD
CY2013Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1000 USD
CY2012Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
2000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
1000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
5000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1719000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1930000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1429000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2617000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1719000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-1930000 USD
us-gaap Net Income Loss
NetIncomeLoss
-1429000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2617000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.13
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.09
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15845000 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14831000 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
120000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
121000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
79000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
163000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4281000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2281000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1237000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
453000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-269000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-359000 USD
prph Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
-576000 USD
prph Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
-1072000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-2572000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-1237000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3541000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-699000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
250000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
232000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-250000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-232000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
195000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
195000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3486000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-931000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5541000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4610000 USD
prph Entity Principal Product Proven Efficiency Percentage Description
EntityPrincipalProductProvenEfficiencyPercentageDescription
Our flagship brand is Cold-EEZE Cold Remedy and our principal product is Cold-EEZE zinc gluconate lozenges, proven in clinical studies to reduce the duration of the common cold by 42%.
us-gaap Use Of Estimates
UseOfEstimates
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <h2 style="PAGE-BREAK-AFTER: auto; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><em>Use of Estimates</em></font></h2> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods.&#160; Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising.&#160; When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (&#8220;Sales Allowances&#8221;), we apply a uniform and consistent method for making certain assumptions for estimating these provisions.&#160; These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared.&#160; Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis.&#160; Actual results could differ from those estimates.</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Our primary product, Cold-EEZE</font><sup><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#210;</font></sup><sup><font style="FONT-SIZE: 10pt"></font></sup><font style="FONT-SIZE: 10pt">lozenges, utilizes a proprietary zinc formulation which has been clinically proven to reduce the duration of the common cold.&#160; Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data.&#160; In addition to Cold-EEZE<sup>&#174;</sup> lozenges, we market and distribute two additional forms of our proprietary zinc formulation, Cold-EEZE<sup>&#174;</sup> QuickMelts<sup>&#174;</sup> and Cold-EEZE<sup>&#174;</sup> Oral Spray.&#160; We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (&#8220;Organix<sup>&#174;</sup>&#8221;). &#160;Each of the Cold-EEZE<sup>&#174;</sup> QuickMelts<sup>&#174;</sup>, Cold-EEZE<sup>&#174;</sup> Oral Spray and Organix<sup>&#174;</sup> products carry shelf-life expiration dates for which we aggregate such product market experience data and update our sales returns and allowances estimates accordingly.&#160; Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. <font style="LETTER-SPACING: -0.15pt">Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</font></font></div> </div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in"> <b><i><font style="FONT-SIZE: 10pt">Concentration of Risks</font></i></b></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC drug, personal care or other products in order to continue to compete on a national level and/or international level.&#160;</font></div> <div style="clear:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. &#160;Our OTC cold remedy products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (&#8220;FDA&#8221;) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; COLOR: black; FONT-SIZE: 12pt; size: 8.5in 11.0in" align="justify"><font style="COLOR: windowtext; FONT-SIZE: 10pt"> &#160;</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; COLOR: black; FONT-SIZE: 12pt; size: 8.5in 11.0in" align="justify"><font style="COLOR: windowtext; FONT-SIZE: 10pt"> Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">We maintain cash and cash equivalents with certain major financial institutions. &#160;As of June 30, 2013, our cash balance was $4.1 million and our bank balance was $<font style=" FONT-SIZE: 10pt">4.4</font> million. &#160;Of the total bank balance, $<font style=" FONT-SIZE: 10pt">696,000</font> was covered by federal depository insurance and $<font style=" FONT-SIZE: 10pt">3.7</font> million was uninsured at June 30, 2013.&#160;</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer&#8217;s financial condition and credit history and generally we do not require collateral.&#160; Our broad range of customers includes many large <font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 12pt"><font size="2"> national chain, regional, specialty and local retail stores</font></font>. &#160;These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us.&#160; At June 30, 2013 and December 31, 2012, our largest accounts receivable balances are with four customers representing approximately <font style=" FONT-SIZE: 10pt">62</font>% and three customers representing <font style=" FONT-SIZE: 10pt">54</font>%, respectively, of our total trade receivable balance.</font></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="clear:both;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 11pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately <font style=" FONT-SIZE: 10pt"> 91</font>% and <font style=" FONT-SIZE: 10pt">91</font>% of total revenues for each of the six months ended June 30, 2013 and 2012, respectively.&#160; A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter.&#160; The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products.&#160; For the three and six months ended June 30, 2013 and 2012, our net sales were principally related to domestic markets.&#160;</font></div> </div>
CY2013Q2 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
1600000 USD
CY2012Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
1000000 USD
CY2013Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1700000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1000000 USD
CY2013Q2 us-gaap Due From Banks
DueFromBanks
4400000 USD
CY2013Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
696000 USD
CY2013Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3700000 USD
us-gaap Sales Allowances Goods
SalesAllowancesGoods
65000 USD
CY2012 us-gaap Sales Allowances Goods
SalesAllowancesGoods
109000 USD
CY2013Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
527000 USD
CY2012Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
679000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
4400000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
4100000 USD
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
40000 USD
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
75000 USD
CY2012Q4 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
2100000 USD
CY2012Q4 prph Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
100000 pure
CY2012Q4 prph Additional Royalties And Commissions Accrual Interest Percentage
AdditionalRoyaltiesAndCommissionsAccrualInterestPercentage
0.0325 pure
CY2012 prph Settlement Benefit
SettlementBenefit
1000000 USD
CY2012Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3500000 USD
CY2013Q2 prph Additional Annual Installment Includes In Other Current Liability
AdditionalAnnualInstallmentIncludesInOtherCurrentLiability
300000 USD
CY2012Q4 prph Additional Annual Installment Includes In Other Current Liability
AdditionalAnnualInstallmentIncludesInOtherCurrentLiability
100000 USD
CY2013Q2 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
612000 USD
CY2013Q2 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1125000 USD
CY2013Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
655000 USD
CY2013Q2 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
100000 USD
CY2013Q2 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
2492000 USD
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
45
prph Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement
EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement
0.15 pure
CY2012Q4 prph Maximum Number Of Common Stock Authorized For Issuance Over36 Months
MaximumNumberOfCommonStockAuthorizedForIssuanceOver36Months
2500000 shares
CY2012Q4 prph Maximum Amount Entitled To Put To Investor In One Draw Down Notice Percentage Of Average Daily Volume On Trading Day
MaximumAmountEntitledToPutToInvestorInOneDrawDownNoticePercentageOfAverageDailyVolumeOnTradingDay
5 pure
CY2012Q4 prph Maximum Amount Entitled To Put To Investor In One Draw Down Notice
MaximumAmountEntitledToPutToInvestorInOneDrawDownNotice
250000 USD
CY2012Q4 prph Equity Line Purchase Price Percentage
EquityLinePurchasePricePercentage
0.95 pure
CY2012Q4 prph Investor Right To Use Excess Proceeds Maximum Percentage
InvestorRightToUseExcessProceedsMaximumPercentage
0.05 pure
CY2012Q4 prph Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit
SharePurchasePutRestrictionsMaximumPercentageOfOwnershipHeldByInvestorToPurchaseSharesInEquityLineOfCredit
0.0999 pure
CY2013Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1491278 shares
prph Cash Less Exercise Of Right Terms
CashLessExerciseOfRightTerms
In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company, a stockholder may exchange one Right for one common share of the Company.
prph Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms
ShareBasedCompensationArrangementByShareBasedPaymentOptionExpirationTerms
No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock.
CY2013Q2 prph Deferred Tax Benefits From Options And Warrants Exercises
DeferredTaxBenefitsFromOptionsAndWarrantsExercises
6400000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
37700000 USD
CY2013Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
21400000 USD
prph Operating Loss Carry Forwards Expiration Dates Description
OperatingLossCarryForwardsExpirationDatesDescription
Fiscal 2020 through 2032
prph Ownership Percentage In Joint Venture
OwnershipPercentageInJointVenture
0.5 pure
CY2010 prph Payments To Fund Joint Venture Investments
PaymentsToFundJointVentureInvestments
500000 USD
CY2010 prph Maximum Amount Committed Towards Contributions In Joint Venture
MaximumAmountCommittedTowardsContributionsInJointVenture
2000000 USD
CY2013Q2 prph Warrants And Options Outstanding
WarrantsAndOptionsOutstanding
1301500 USD
CY2012Q2 prph Warrants And Options Outstanding
WarrantsAndOptionsOutstanding
1312750 USD
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
359271 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20962 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
401849 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
56363 shares
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1719000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1930000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1429000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2617000 USD
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15845000 shares
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14831000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15799000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14811000 shares
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2013Q2 prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
CY2012Q2 prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
CY2013Q2 prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
0 shares
CY2012Q2 prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
0 shares
prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
0 shares
prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
0 shares
CY2013Q2 prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
CY2012Q2 prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1719000 USD
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1930000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1429000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2617000 USD
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15845000 shares
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14831000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15799000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14811000 shares
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18

Files In Submission

Name View Source Status
0001144204-13-045279-index-headers.html Edgar Link pending
0001144204-13-045279-index.html Edgar Link pending
0001144204-13-045279.txt Edgar Link pending
0001144204-13-045279-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
prph-20130630.xml Edgar Link completed
prph-20130630.xsd Edgar Link pending
prph-20130630_cal.xml Edgar Link unprocessable
prph-20130630_def.xml Edgar Link unprocessable
prph-20130630_lab.xml Edgar Link unprocessable
prph-20130630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
v351584_10q.htm Edgar Link pending
v351584_ex31-1.htm Edgar Link pending
v351584_ex31-2.htm Edgar Link pending
v351584_ex32-1.htm Edgar Link pending
v351584_ex32-2.htm Edgar Link pending